Canadian clinical practice guidelines for invasive candidiasis in adults

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 21, Issue 4, 2010, Pages

  Bow, Eric J ^a,b,c   Evans, Gerald ^d   Fuller, Jeff ^e   Laverdière, Michel ^f   Rotstein, Coleman ^g   Rennie, Robert ^e   Shafran, Stephen D ^h   Sheppard, Don ⁱ   Carle, Sylvie ^f   Phillips, Peter ^j   Vinh, Donald C ^i,k  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CANCERCARE MANITOBA   (Canada)

^c WINNIPEG REGIONAL HEALTH AUTHORITY   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ MCGILL UNIVERSITY   (Canada)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^k Laboratory of Clinical Infectious Diseases   (Canada)

more..

Author keywords

Adults; Candidiasis; Epidemiology; Guidelines; Prophylaxis; Therapy

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ASTEMIZOLE; BENZODIAZEPIN 2 ONE DERIVATIVE; BENZODIAZEPINE; CARBAMAZEPINE; CASPOFUNGIN; CISAPRIDE; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; GLIBENCLAMIDE; GLIPIZIDE; ITRACONAZOLE; MICAFUNGIN; PHENYTOIN; PIMOZIDE; POSACONAZOLE; PYRROLE DERIVATIVE; RIFABUTIN; RIFAMPICIN; TACROLIMUS; TERFENADINE; THEOPHYLLINE; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ADULT; ADULT DISEASE; ANTIFUNGAL RESISTANCE; CANCER CHEMOTHERAPY; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CHILL; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG FEVER; GRAFT RECIPIENT; HEALTH CARE SYSTEM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; LEUKEMIA; LOADING DRUG DOSE; NEPHROTOXICITY; NEUTROPENIA; PANCREAS TRANSPLANTATION; PRACTICE GUIDELINE; REVIEW; RIGOR; RISK FACTOR; TREATMENT DURATION;

EID: 79953245751     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2010/357076     Document Type: Review

References (413)

1. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-35.
2. Girmenia C, Barosi G, Aversa F, et al. Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: Results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Clin Infect Dis 2009;49:1226-36.
3. Denning DW, Kibbler CC, Barnes RA. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 2003;3:230-40. (Pubitemid 36389186)
4. Bohme A, Ruhnke M, Buchheidt D, et al. Treatment of invasive fungal infections in cancer patients - recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009;88:97-110.
5. Fluckiger U, Marchetti O, Bille J, et al. Treatment options of invasive fungal infections in adults. Swiss Med Wkly 2006;136:447-63. (Pubitemid 44220568)
6. Herbrecht R, Fluckiger U, Gachot B, Ribaud P, Thiebaut A, Cordonnier C. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur J Cancer Suppl 2007;5:49-59. (Pubitemid 47187744)
7. Link H, Bohme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003;(82 Suppl 2):S105-S117.
8. Santolaya ME, Rabagliati R, Bidart T, et al. [Consensus: Rational approach towards the patient with cancer, fever and neutropenia.] Rev Chilena Infectol 2005;(22 Suppl 2):S79-S113.
9. Slavin MA, Szer J, Grigg AP, et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern Med J 2004;34:192-200. (Pubitemid 38651040)
10. Montero JG, Gil CL. Resumen de las recomendaciones terapéuticas para infecciones fúngicas en el paciente crítico no neutropénico: Una visión multidisciplinar. Farmacia Hospitalaria 2005;29:283-9.
11. National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections. National Comprehensive Cancer Network, 2007.
12. Jun HX, Zhixiang S, Chun W, et al. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever. Int J Antimicrob Agents 2005;(26 Suppl 2):S128-S132. (Pubitemid 41606723)
13. Gavalda J, Ruiz I. [Guidelines for the treatment of infection due to Aspergillus spp.] Enferm Infecc Microbiol Clin 2003;21:571-8.
14. The Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Assoc J 1979;121:1193-254.
15. de Meyrick J. The Delphi method and health research. Health Edu 2003;103:7-16.
16. Zaoutis TE, Greves HM, Lautenbach E, Bilker WB, Coffin SE. Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J 2004;23:635-41. (Pubitemid 38924888)
17. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidemia in Europe: Epidemiology and resistance. Int J Antimicrob Agents 2006;27:359-66.
18. Wisplinghoff H, Seifert H, Tallent SM, Bischoff T, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in pediatric patients in United States hospitals: Epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 2003;22:686-91. (Pubitemid 36999643)
19. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003;3:685-702. (Pubitemid 37345347)
20. Colombo AL, Nucci M, Park BJ, et al. Epidemiology of candidemia in Brazil: A nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006;44:2816-23. (Pubitemid 44228575)
21. Laupland KB, Gregson DB, Church DL, Ross T, Elsayed S. Invasive Candida species infections: A 5 year population-based assessment. J Antimicrob Chemother 2005;56:532-7. (Pubitemid 41264132)
22. Almirante B, Rodriguez D, Park BJ, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: Results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005;43:1829-35.
23. Shetty SS, Harrison LH, Hajjeh RA, et al. Determining risk factors for candidemia among newborn infants from population-based surveillance: Baltimore, Maryland, 1998-2000. Pediatr Infect Dis J 2005;24:601-4.
24. Arendrup MC, Fuursted K, Gahrn-Hansen B, et al. Seminational surveillance of fungemia in Denmark: Notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 2005;43:4434-40. (Pubitemid 41298224)
25. Saiman L, Ludington E, Dawson JD, et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001;20:1119-24. (Pubitemid 34016422)
26. Marchetti O, Bille J, Fluckiger U, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004;38:311-20.
27. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: Results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002;40:3489-92. (Pubitemid 34977475)
28. Karlowsky JA, Zhanel GG, Klym KA, Hoban DJ, Kabani AM. candidemia in a Canadian tertiary care hospital from 1976 to 1996. Diagn Microbiol Infect Dis 1997;29:5-9.
29. Wu CJ, Lee HC, Lee NY, et al. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003. J Microbiol Immunol Infect 2006;39:135-43.
30. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis 1999;29:239-44. (Pubitemid 29380177)
31. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007;20:133-63. (Pubitemid 46167771)
32. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17. (Pubitemid 39050477)
33. Laupland KB, Kirkpatrick AW, Church DL, Ross T, Gregson DB. Intensive-care-unit-acquired bloodstream infections in a regional critically ill population. J Hosp Infect 2004;58:137-45. (Pubitemid 39317884)
34. Lyytikainen O, Lumio J, Sarkkinen H, Kolho E, Kostiala A, Ruutu P. Nosocomial bloodstream infections in Finnish hospitals during 1999-2000. Clin Infect Dis 2002;35:e14-e19.
35. Service PHL. Nosocomial infection national surveillance service: Surveillance of hospital-acquired bacteremia in English hospitals between 1997-2002. Public Health Laboratory Services, 2002.
36. Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002;40:1298-302. (Pubitemid 34279892)
37. Poikonen E, Lyytikainen O, Anttila VJ, Ruutu P. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003;9:985-90.
38. Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsaker T, Gaustad P. 2006. Candidemia in Norway (1991 to 2003): Results from a nationwide study. J Clin Microbiol 44:1977-81.
39. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.
40. Martin D, Persat F, Piens MA, Picot S. Candida species distribution in bloodstream cultures in Lyon, France, 1998-2001. Eur J Clin Microbiol Infect Dis 2005;24:329-33.
41. San Miguel LG, Cobo J, Otheo E, Sanchez-Sousa A, Abraira V, Moreno S. Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: Emergence of Candida parapsilosis. Infect Control Hosp Epidemiol 2005;26:548-52.
42. Garbino J, Kolarova L, Rohner P, Lew D, Pichna P, Pittet D. Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine (Baltimore) 2002;81:425-33. (Pubitemid 35285962)
43. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-30.
44. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008;112:2493-9.
45. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999;28:1071-9.
46. Rodriguez D, Almirante B, Park BJ, et al. Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr Infect Dis J 2006;25:224-9. (Pubitemid 43379062)
47. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000;181:309-16. (Pubitemid 30049062)
48. Laverdiere M, Rotstein C, Bow EJ, et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study. J Antimicrob Chemother 2000;46:1001-8. (Pubitemid 32000613)
49. Testore GP, Falco F, Sarrecchia C, Sordillo P, Bontempo G, Andreoni M. Two-year surveillance on fluconazole susceptibility of Candida spp isolates in a general and university hospital in Rome. Diagn Microbiol Infect Dis 2001;41:23-7. (Pubitemid 33001455)
50. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997;24:1122-8. (Pubitemid 127774267)
51. Chen S, Slavin M, Nguyen Q, et al. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006;12:1508-16.
52. Tortorano AM, Peman J, Bernhardt H, et al. Epidemiology of candidemia in Europe: Results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004;23:317-22. (Pubitemid 38669942)
53. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004;42:1519-27.
54. Sofair AN, Lyon GM, Huie-White S, et al. Epidemiology of community-onset candidemia in Connecticut and Maryland. Clin Infect Dis 2006;43:32-9. (Pubitemid 43939073)
55. Diekema DJ, MA Pfaller. Nosocomial candidemia: An ounce of prevention is better than a pound of cure. Infect Control Hosp Epidemiol 2004;25:624-6. (Pubitemid 39095042)
56. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37:1172-7. (Pubitemid 37372504)
57. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidemia: A case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005;26:540-7. (Pubitemid 40896144)
58. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998;27:781-8. (Pubitemid 29244335)
59. Zaoutis TE, Coffin SE, Chu JH, et al. Risk factors for mortality in children with candidemia. Pediatr Infect Dis J 2005;24:736-9. (Pubitemid 41140963)
60. Rotstein C, Cragin L, Laverdiere M, et al. Economic evaluation of voriconazole for the treatment of candidemia in Canadian patients. Can J Infect Dis Med Microbiol 2008;19:219-26.
61. Krause W, Matheis H, Wulf K. Fungaemia and funguria after oral administration of Candida albicans. Lancet 1969;1:598-9.
62. Lillegard JB, Sim RB, Thorkildson P, Gates MA, Kozel TR. Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo. J Infect Dis 2006;193:1589-97. (Pubitemid 43794589)
63. Lee SJ, Gonzalez-Aseguinolaza G, Nussenzweig MC. Disseminated candidiasis and hepatic malarial infection in mannose-bindinglectin- A-deficient mice. Mol Cell Biol 2002;22:8199-203. (Pubitemid 35304053)
64. Edwards JE Jr, Gaither TA, O'Shea JJ, et al. Expression of specific binding sites on Candida with functional and antigenic characteristics of human complement receptors. J Immunol 1986;137:3577-83. (Pubitemid 17193319)
65. Kozel TR, Weinhold LC, Lupan DM. Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans. Infect Immun 1996;64:3360-8. (Pubitemid 26256188)
66. Gelfand JA, Hurley DL, Fauci AS, Frank MM. Role of complement in host defense against experimental disseminated candidiasis. J Infect Dis 1978;138:9-16. (Pubitemid 8399822)
67. Kozel TR, MacGill RS, Percival A, Zhou Q. Biological activities of naturally occurring antibodies reactive with Candida albicans mannan. Infect Immun 2004;72:209-18. (Pubitemid 38018178)
68. Netea MG, Van der Graaf CA, Vonk AG, Verschueren I, van der Meer JW, Kullberg BJ. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis 2002;185:1483-9. (Pubitemid 34507972)
69. Jouault T, Ibata-Ombetta S, Takeuchi O, et al. Candida albicans phospholipomannan is sensed through toll-like receptors. J Infect Dis 2003;188:165-72. (Pubitemid 36829757)
70. Netea MG, Sutmuller R, Hermann C, et al. Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol 2004;172:3712-8. (Pubitemid 38337955)
71. Spellberg B, Johnston D, Phan QT, et al. Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis. Infect Immun 2003;71:5756-64. (Pubitemid 37205629)
72. Brown GD, Gordon S. Immune recognition. A new receptor for beta-glucans. Nature 2001;413:36-7.
73. McGreal EP, Rosas M, Brown GD, et al. The carbohydraterecognition domain of Dectin-2 is a C-type lectin with specificity for high mannose. Glycobiology 2006;16:422-30.
74. Cambi A, Gijzen K, de Vries JM, et al. The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. Eur J Immunol 2002;33:532-8.
75. Baccarini M, Blasi E, Puccetti P, Bistoni F. Phagocytic killing of Candida albicans by different murine effector cells. Sabouraudia 1983;21:271-86.
76. Cohen MS, Isturiz RE, Malech HL, et al. Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am J Med 1981;71:59-66. (Pubitemid 12254714)
77. Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000;79:155-69.
78. Kim MH, Rodey GE, Good RA, Chilgren RA, Quie PG. Defective candidacidal capacity of polymorphonuclear leukocytes in chronic granulomatous disease of childhood. J Pediatr 1969;75:300-3.
79. Wysong DR, Christin L, Sugar AM, Robbins PW, Diamond RD. Cloning and sequencing of a Candida albicans catalase gene and effects of disruption of this gene. Infect Immun 1998;66:1953-61. (Pubitemid 28194088)
80. Tosado-Acevedo R, Toranzos GA, Alsina A. Extraction and purification of a catalase from Candida albicans. PR Health Sci J 1992;11:77-80.
81. Lorenz MC, Fink GR. The glyoxylate cycle is required for fungal virulence. Nature 2001;412:83-6. (Pubitemid 32851514)
82. Ibrahim AS, Filler SG, Sanglard D, Edwards JE Jr, Hube B. Secreted aspartyl proteinases and interactions of Candida albicans with human endothelial cells. Infect Immun 1998;66:3003-5. (Pubitemid 28261818)
83. Filler SG, Swerdloff JN, Hobbs C, Luckett PM. Penetration and damage of endothelial cells by Candida albicans. Infect Immun 1995;63:976-83.
84. Mayer CL, Filler SG, Edwards JE Jr. Candida albicans adherence to endothelial cells. Microvasc Res 1992;43:218-26.
85. Filler SG, Pfunder AS, Spellberg BJ, Spellberg JP, Edwards JE Jr. Candida albicans stimulates cytokine production and leukocyte adhesion molecule expression by endothelial cells. Infect Immun 1996;64:2609-17. (Pubitemid 26226824)
86. Cannom RR, French SW, Johnston D, Edwards JE Jr, Filler SG. Candida albicans stimulates local expression of leukocyte adhesion molecules and cytokines in vivo. J Infect Dis 2002;186:389-96. (Pubitemid 34816322)
87. Phan QT, Fratti RA, Prasadarao NV, Edwards JE Jr, Filler SG. N-cadherin mediates endocytosis of Candida albicans by endothelial cells. J Biol Chem 2005;280:10455-61. (Pubitemid 40395903)
88. Ibrahim AS, Mirbod F, Filler S, et al. Evidence implicating phospholipase as a virulence factor of Candida albicans. Infect Immun 1995;63:1993-8.
89. Fu Y, Ibrahim AS, Fonzi W, Zhou X, Ramos CF, Ghannoum MA. Cloning and characterization of a gene (LIP1) which encodes a lipase from the pathogenic yeast Candida albicans. Microbiology 1997;143:331-40. (Pubitemid 27092168)
90. Tumbarello M, Posteraro B, Trecarichi EM, et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol 2007;45:1843-50. (Pubitemid 46933916)
91. DeKruijff B, Demel RA. Polyene antibiotic-sterol interactions in membranes of Acholeplasma laidlawaii cells and lecithin liposomes. III. Molecular structure of the polyene antibiotic-cholesterol complexes. Biochim Biophys Acta 1974;339:57-70.
92. Holz RW. The effects of the polyene antibiotic nystatin and amphotericin B on thin lipid membranes. Ann NY Acad Sci 1974;235:469-79.
93. Kerridge D. The plasma membrane of Candida albicans and its role in the action of antifungal drugs. In: Gooday GW, Lloyd D, Trinci APJ, eds. The Eukaryotic Microbial Cell. Cambridge: Cambridge University Press, 1980.
94. Kerridge D. The protoplast membrane and antifungal drugs. In: Peberdy JF, Ferenczy I, eds. Fungal Protoplast Applications in Biochemistry and Genetics. New York: Marcel Dekker Inc, 1985.
95. Liao RS, Rennie RP, Talbot JA. Assessment of the effect of amphotericin B on the vitality of Candida albicans. Antimicrob Agents Chemother 1999;43:1034-41. (Pubitemid 29214722)
96. Liao RS, Rennie RP, Talbot JA. Sublethal injury and resuscitation of Candida albicans after amphotericin B treatment. Antimicrob Agents Chemother 2003;47:1200-6. (Pubitemid 36368575)
97. Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002;35:359-66. (Pubitemid 34852563)
98. Hitchcock CA, Dickinson K, Brown SB, Evans EG, Adams DJ. Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans. Biochem J 1990;266:475-80. (Pubitemid 20090149)
99. Sanati H, Belanger P, Fratti R, Ghannoum M. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997;41:2492-6.
100. Geber A, Hitchcock CA, Swartz JE, et al. Deletion of the Candida glabrata ERG3 and ERG11 genes: Effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob Agents Chemother 1995;39:2708-17.
101. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999;12:40-79. (Pubitemid 29055953)
102. Beggs WH. Comparison of miconazole- and ketoconazole-induced release of K+ from Candida species. J Antimicrob Chemother 1983;11:381-3. (Pubitemid 13119111)
103. Ghannoum MA, Spellberg BJ, Ibrahim AS, et al. Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole. Antimicrob Agents Chemother 1994;38:2029-33. (Pubitemid 24278796)
104. Vanden BH, Marichal P, Le JL, Coene MC, Gorrens J, Cools W. Effects of itraconazole on cytochrome P-450-dependent sterol 14 alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans. Antimicrob Agents Chemother 1993;37:2101-5. (Pubitemid 23298196)
105. Hoffman HL, Ernst EJ, Klepser ME. Novel triazole antifungal agents. Expert Opin Investig Drugs 2000;9:593-605. (Pubitemid 30119696)
106. Dodds Ashley ES, Alexander BD. Posaconazole. Drugs Today (Barc) 2005;41:393-400.
107. Hector RF. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993;6:1-21. (Pubitemid 23055191)
108. Pfaller M, Riley J, Koerner T. Effects of cilofungin (LY121019) on carbohydrate and sterol composition of Candida albicans. Eur J Clin Microbiol Infect Dis 1989;8:1067-70. (Pubitemid 20018481)
109. Cassone A, Mason RE, Kerridge D. Lysis of growing yeast-form cells of Candida albicans by echinocandin: A cytological study. Sabouraudia 1982;19:97-110.
110. Denning DW. Echinocandin antifungal drugs. Lancet 2003;362:1142-51. (Pubitemid 37222342)
111. Polak A, Scholer HJ. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy 1975;21:113-30.
112. Diasio R, Bennett J, Myers C. Mode of action of 5-fluorocytosine. Biochim Biophys Acta 1978;27:703-7. (Pubitemid 8313181)
113. Michaelis S, Berkower C. Sequence comparison of yeast ATP-binding cassette proteins. Cold Spring Harb Symp Quant Biol 1995;60:291-307. (Pubitemid 26202040)
114. Dick JD, Merz WG, Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 1980;18:158-63. (Pubitemid 10039804)
115. Orozco AS, Higginbotham LM, Hitchcock CA, et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 1998;42:2645-9. (Pubitemid 28462908)
116. Vanden BH, Marichal P, Odds FC, Le JL, Coene MC. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 1992;36:2602-10.
117. White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 1997;41:1482-7.
118. Parkinson T, Falconer DJ, Hitchcock CA. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob Agents Chemother 1995;39:1696-9.
119. Clark FS, Parkinson T, Hitchcock CA, Gow NA. Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: Possible role for drug efflux in drug resistance. Antimicrob Agents Chemother 1996;40:419-25. (Pubitemid 26049356)
120. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995;39:2378-86.
121. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006;50:2058-63. (Pubitemid 43807526)
122. Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006;50:2522-4. (Pubitemid 43993195)
123. Daneman N, Chan AK, Poutanen SM, Rennie R, Sand C, Porter S. The emergence of caspofungin resistance during treatment of recurrent Candida glabrata candidaemia. 16th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), 2006. (Abst)
124. Thompson GR III, Wiederhold NP, Vallor AC, Villareal NC, Lewis JS, Patterson TF. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother 2008;52:3783-5.
125. Hernandez S, Lopez-Ribot JL, Najvar JK, McCarthy DI, Bocanegra R, Graybill JR. Caspofungin resistance in Candida albicans: Correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004;48:1382-3. (Pubitemid 38405501)
126. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006;57:705-8.
127. Iwata K. Drug resistance in human pathogenic fungi. Eur J Epidemiol 1992;8:407-21.
128. Whelan WL. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans. Crit Rev Microbiol 1987;15:45-56.
129. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; third informational supplement. Wayne: Clinical and Laboratory Standards Institute, 2008.
130. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997;24:235-47. (Pubitemid 127774263)
131. Pfaller MA, Diekema DJ, Rex JH, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: Analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006;44:819-26.
132. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: A blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006;19:435-47.
133. Alexander BD, Schell WA, Miller JL, Long GD, Perfect JR. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 2005;80:868-71. (Pubitemid 41443773)
134. Magill SS, Shields C, Sears CL, Choti M, Merz WG. Triazole cross-resistance among Candida spp.: Case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006;44:529-35. (Pubitemid 43222248)
135. Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M, Marr KA. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006;44:1740-3. (Pubitemid 43726263)
136. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: Report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol 2003;41:1440-6. (Pubitemid 36428086)
137. Pfaller MA, Messer SA, Boyken L, Huynh H, Hollis RJ, Diekema DJ. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: Global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 2002;46:3518-21.
138. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47:3149-54. (Pubitemid 37229571)
139. Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: Trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002;40:3551-7.
140. Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: Global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004;(10 Suppl 1):11-23. (Pubitemid 38386593)
141. Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004;48:201-5.
142. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J Clin Microbiol 2003;41:2176-9. (Pubitemid 36576559)
143. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: An 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007;45:1735-45.
144. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: Global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. J Clin Microbiol 2005;43:3807-10.
145. Pfaller MA, Messer SA, Boyken L, et al. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods. J Clin Microbiol 2007;45:70-5. (Pubitemid 46106408)
146. Park BJ, Arthington-Skaggs BA, Hajjeh RA, et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother 2006;50:1287-92.
147. Yang YL, Li SY, Cheng HH, Lo HJ. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002. Diagn Microbiol Infect Dis 2005;51:179-83.
148. Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006;42:244-51. (Pubitemid 43054198)
149. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006;42:938-44.
150. Pfaller MA, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Diekema DJ. Evaluation of the etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species. J Clin Microbiol 2004;42:4977-9. (Pubitemid 39506198)
151. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: A global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004;42:3142-6. (Pubitemid 38938071)
152. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-89. (Pubitemid 38113025)
153. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: Analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008;46:2620-9.
154. Kartsonis N, Killar J, Mixson L, et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: Relationship of MIC to treatment outcome. Antimicrob Agents Chemother 2005;49:3616-23. (Pubitemid 41233008)
155. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of Candida spp. to caspofungin: Four years of global surveillance. J Clin Microbiol 2006;44:760-3.
156. Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 2000;44:1108-11. (Pubitemid 30165304)
157. Pfaller MA, Messer SA, Boyken L, et al. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J Clin Microbiol 2004;42:3117-9. (Pubitemid 38938067)
158. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9. (Pubitemid 35461658)
159. Odds FC, Motyl M, Andrade R, et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol 2004;42:3475-82. (Pubitemid 39045669)
160. Nivoix Y, Leveque D, Herbrecht R, Koffel JC, Beretz L, Ubeaud-Sequier G. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008;47:779-92.
161. Dodds Ashley E, Lewis R, Lewis J, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006;43:S28-S39. (Pubitemid 44078894)
162. Goodwin ML, Drew RH. Antifungal serum concentration monitoring: An update. J Antimicrob Chemother 2008;61:17-25.
163. Smith J. Pharmacokinetics of antifungals: Implications for drug selection (drug overview). Infect Med 2006;23:328-33. (Pubitemid 46391170)
164. Black KE, Baden LR. Fungal infections of the CNS: Treatment strategies for the immunocompromised patient. CNS Drugs 2007;21:293-318. (Pubitemid 46598450)
165. Louria DB, Stiff DP, Bennett B. Disseminated moniliasis in the adult. Medicine (Baltimore) 1962;41:307-37.
166. Gaines JD, Remington JS. Disseminated candidiasis in the surgical patient. Surgery 1972;72:730-6.
167. Ascioglu S, Rex JH, De PB, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002;34:7-14. (Pubitemid 33152659)
168. Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis 1993;17:103-9. (Pubitemid 23294544)
169. Pfaller MA, Houston A, Coffmann S. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata. J Clin Microbiol 1996;34:58-61. (Pubitemid 126506893)
170. Cardenes CD, Carrillo AJ, Arias A, et al. Comparison of albicans ID2 agar plate with the germ tube for presumptive identification of Candida albicans. Diagn Microbiol Infect Dis 2002;42:181-5. (Pubitemid 34261123)
171. Wilson DA, Joyce MJ, Hall LS, et al. Multicenter evaluation of a Candida albicans peptide nucleic acid fluorescent in situ hybridization probe for characterization of yeast isolates from blood cultures. J Clin Microbiol 43:2909-12.
172. Sheppard DC, Locas MC, Restieri C, Laverdiere M. Utility of the germ tube test for direct identification of Candida albicans from positive blood culture bottles. J Clin Microbiol 2008;46:3508-9.
173. Terlecka JA, du Cros PA, Orla MC, Spelman D. Rapid differentiation of Candida albicans from non-albicans species by germ tube test directly from BacTAlert blood culture bottles. Mycoses 2007;50:48-51.
174. Solomkin JS, Flohr AM, Simmons RL. Indications for therapy for fungemia in postoperative patients. Arch Surg 1982;117:1272-5. (Pubitemid 12036928)
175. Martino P, Girmenia C, Micozzi A, et al. Fungemia in patients with leukemia. Am J Med Sci 1993;306:225-32. (Pubitemid 23305975)
176. Golan Y, Wolf MP, Pauker SG, Wong JB, Hadley S. Empirical anti-Candida therapy among selected patients in the intensive care unit: A cost-effectiveness analysis. Ann Intern Med 2005;143:857-69. (Pubitemid 46202221)
177. Pittet D, Garbino J. Fungal infections in the critically ill. Curr Opin Crit Care 1995;1:369-80.
178. Kontoyiannis DP, Luna MA, Samuels BI, Bodey GP. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin North Am 2000;14:721-39.
179. Masood A, Sallah S. Chronic disseminated candidiasis in patients with acute leukemia: Emphasis on diagnostic definition and treatment. Leuk Res 2005;29:493-501. (Pubitemid 40327237)
180. Yeo SF, Wong B. Current status of nonculture methods for diagnosis of invasive fungal infections. Clin Microbiol Rev 2002;15:465-84. (Pubitemid 34761353)
181. Phillips P, Dowd A, Jewesson P, et al. Nonvalue of antigen detection immunoassays for diagnosis of candidemia. J Clin Microbiol 1990;28:2320-6. (Pubitemid 20299129)
182. Bougnoux ME, Hill C, Moissenet D, et al. Comparison of antibody, antigen, and metabolite assays for hospitalized patients with disseminated or peripheral candidiasis. J Clin Microbiol 1990;28:905-9.
183. Morace G, Pagano L, Sanguinetti M, et al. PCR-restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with hematological malignancies. J Clin Microbiol 1999;37:1871-5. (Pubitemid 29235238)
184. Alexander BD. Diagnosis of fungal infection: New technologies for the mycology laboratory. Transpl Infect Dis 2002;(4 Suppl 3):32-7. (Pubitemid 34832434)
185. Walsh TJ, Hathorn JW, Sobel JD, et al. Detection of circulating Candida enolase by immunoassay in patients with cancer and invasive candidiasis. N Engl J Med 1991;324:1026-31.
186. Mitsutake K, Miyazaki T, Tashiro T, et al. Enolase antigen, mannan antigen, Cand-Tec antigen, and beta-glucan in patients with candidemia. J Clin Microbiol 1996;34:1918-21. (Pubitemid 26239223)
187. Sendid B, Caillot D, Baccouch-Humbert B, et al. Contribution of the Platelia Candida-specific antibody and antigen tests to early diagnosis of systemic Candida tropicalis infection in neutropenic adults. J Clin Microbiol 2003;41:4551-8. (Pubitemid 37259756)
188. Senn L, Robinson JO, Schmidt S, et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008;46:878-85.
189. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004;39:199-205. (Pubitemid 38971490)
190. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005;41:654-9. (Pubitemid 41170353)
191. Pickering JW, Sant HW, Bowles CA, Roberts WL, Woods GL. Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005;43:5957-62. (Pubitemid 43100644)
192. Fridkin SK. Candidemia is costly - plain and simple. Clin Infect Dis 2005;41:1240-1. (Pubitemid 41532665)
193. Voss A, Hollis RJ, Pfaller MA, Wenzel RP, Doebbeling BN. Investigation of the sequence of colonization and candidemia in nonneutropenic patients. J Clin Microbiol 1994;32:975-80. (Pubitemid 24100072)
194. Nucci M, Anaissie E. Revisiting the source of candidemia: Skin or gut? Clin Infect Dis 2001;33:1959-67.
195. Cole GT, Halawa AA, Anaissie EJ. The role of the gastrointestinal tract in hematogenous candidiasis: From the laboratory to the bedside. Clin Infect Dis 1996;(22 Suppl 2):S73-S88. (Pubitemid 26256437)
196. Martino P, Girmenia C, Micozzi A, De BF, Boccanera M, Cassone A. Prospective study of Candida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients. Eur J Clin Microbiol Infect Dis 1994;13:797-804. (Pubitemid 24359435)
197. Martino P, Girmenia C, Venditti M, et al. Candida colonization and systemic infection in neutropenic patients. A retrospective study. Cancer 1989;64:2030-4. (Pubitemid 19280400)
198. Lass-Florl C, Gunsilius E, Gastl G, et al. Fungal colonization in neutropenic patients: A randomized study comparing itraconazole solution and amphotericin B solution. Ann Hematol 2003;82:565-9. (Pubitemid 37220674)
199. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994;220:751-8. (Pubitemid 24376373)
200. Reagan DR, Pfaller MA, Hollis RJ, Wenzel RP. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J Clin Microbiol 1990;28:2733-8.
201. Chen YC, Chang SC, Tai HM, Hsueh PR, Luh KT. Molecular epidemiology of Candida colonizing critically ill patients in intensive care units. J Formos Med Assoc 2001;100:791-7.
202. Pittet D, Monod M, Filthuth I, Frenk E, Suter PM, Auckenthaler R. Contour-clamped homogeneous electric field gel electrophoresis as a powerful epidemiologic tool in yeast infections. Am J Med 1991;91:256S-263S.
203. Cerikcioglu N, Ilki A, Bilgen H, Ozek E, Metin F, Kalaca S. The relationships between candidemia and candidal colonization and virulence factors of the colonizing strains in preterm infants. Turk J Pediatr 2004;46:245-50. (Pubitemid 39276582)
204. Fanello S, Bouchara JP, Jousset N, Delbos V, LeFlohic AM. Nosocomial Candida albicans acquisition in a geriatric unit: Epidemiology and evidence for person-to-person transmission. J Hosp Infect 2001;47:46-52.
205. Betremieux P, Chevrier S, Quindos G, Sullivan D, Polonelli L, Guiguen C. Use of DNA fingerprinting and biotyping methods to study a Candida albicans outbreak in a neonatal intensive care unit. Pediatr Infect Dis J 1994;13:899-905. (Pubitemid 24322789)
206. Huang YC, Lin TY, Leu HS, Peng HL, Wu JH, Chang HY. Outbreak of Candida parapsilosis fungemia in neonatal intensive care units: Clinical implications and genotyping analysis. Infection 1999;27:97-102.
207. Huang YC, Lin TY, Peng HL, Wu JH, Chang HY, Leu HS. Outbreak of Candida albicans fungaemia in a neonatal intensive care unit. Scand J Infect Dis 1998;30:137-42.
208. Barchiesi F, Caggiano G, Falconi Di Francesco L, Montagna MT, Barbuti S, Scalise G. Outbreak of fungemia due to Candida parapsilosis in a pediatric oncology unit. Diagn Microbiol Infect Dis 2004;49:269-71. (Pubitemid 39094618)
209. Posteraro B, Bruno S, Boccia S, et al. Candida parapsilosis bloodstream infection in pediatric oncology patients: Results of an epidemiologic investigation. Infect Control Hosp Epidemiol 2004;25:641-5. (Pubitemid 39095045)
210. Diekema DJ, Messer SA, Hollis RJ, Wenzel RP, Pfaller MA. An outbreak of Candida parapsilosis prosthetic valve endocarditis. Diagn Microbiol Infect Dis 1997;29:147-53. (Pubitemid 27519523)
211. Lupetti A, Tavanti A, Davini P, et al. Horizontal transmission of Candida parapsilosis candidemia in a neonatal intensive care unit. J Clin Microbiol 2002;40:2363.
212. Clark TA, Slavinski SA, Morgan J, et al. Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol 2004;42:4468-72. (Pubitemid 39362357)
213. Pertowski CA, Baron RC, Lasker BA, Werner SB, Jarvis WR. Nosocomial outbreak of Candida albicans sternal wound infections following cardiac surgery traced to a scrub nurse. J Infect Dis 1995;172:817-22.
214. Strausbaugh LJ, Sewell DL, Ward TT, Pfaller MA, Heitzman T, Tjoelker R. High frequency of yeast carriage on hands of hospital personnel. J Clin Microbiol 1994;32:2299-300. (Pubitemid 24258486)
215. Huang YC, Lin TY, Leu HS, Wu JL, Wu JH. Yeast carriage on hands of hospital personnel working in intensive care units. J Hosp Infect 1998;39:47-51. (Pubitemid 28242983)
216. Trick WE, Vernon MO, Hayes RA, et al. Impact of ring wearing on hand contamination and comparison of hand hygiene agents in a hospital. Clin Infect Dis 2003;36:1383-90. (Pubitemid 36702871)
217. Traore O, Springthorpe VS, Sattar SA. A quantitative study of the survival of two species of Candida on porous and non-porous environmental surfaces and hands. J Appl Microbiol 2002;92:549-55. (Pubitemid 34227148)
218. Bart-Delabesse E, van Deventer H, Goessens W, et al. Contribution of molecular typing methods and antifungal susceptibility testing to the study of a candidemia cluster in a burn care unit. J Clin Microbiol 1995;33:3278-83.
219. Sherertz RJ, Gledhill KS, Hampton KD, et al. Outbreak of Candida bloodstream infections associated with retrograde medication administration in a neonatal intensive care unit. J Pediatr 1992;120:455-61.
220. Zancope-Oliveira RM, James MJ, Derossi AP, et al. Strain characterization of Candida parapsilosis fungemia by molecular typing methods. Eur J Clin Microbiol Infect Dis 2000;19:514-20. (Pubitemid 30611993)
221. Yagupsky P, Dagan R, Chipman M, Goldschmied-Reouven A, Zmora E, Karplus M. Pseudooutbreak of Candida guilliermondii fungemia in a neonatal intensive care unit. Pediatr Infect Dis J 1991;10:928-32.
222. Welbel SF, McNeil MM, Kuykendall RJ, et al. Candida parapsilosis bloodstream infections in neonatal intensive care unit patients: Epidemiologic and laboratory confirmation of a common source outbreak. Pediatr Infect Dis J 1996;15:998-1002. (Pubitemid 26403793)
223. Sanchez V, Vazquez JA, Barth-Jones D, Dembry L, Sobel JD, Zervos MJ. Nosocomial acquisition of Candida parapsilosis: An epidemiologic study. Am J Med 1993;94:577-82. (Pubitemid 23166702)
224. Vazquez JA, Dembry LM, Sanchez V, et al. Nosocomial Candida glabrata colonization: An epidemiologic study. J Clin Microbiol 1998;36:421-6. (Pubitemid 28060306)
225. Vazquez JA, Sanchez V, Dmuchowski C, Dembry LM, Sobel JD, Zervos MJ. Nosocomial acquisition of Candida albicans: An epidemiologic study. J Infect Dis 1993;168:195-201. (Pubitemid 23178749)
226. Chowdhary A, Becker K, Fegeler W, et al. An outbreak of candidemia due to Candida tropicalis in a neonatal intensive care unit. Mycoses 2003;46:287-92. (Pubitemid 37204503)
227. Doi M, Homma M, Iwaguchi S, Horibe K, Tanaka K. Strain relatedness of Candida albicans strains isolated from children with leukemia and their bedside parents. J Clin Microbiol 1994;32:2253-9. (Pubitemid 24258475)
228. Marco F, Lockhart SR, Pfaller MA, et al. Elucidating the origins of nosocomial infections with Candida albicans by DNA fingerprinting with the complex probe Ca3. J Clin Microbiol 1999;37:2817-28. (Pubitemid 29391894)
229. Verduyn Lunel FM, Meis JF, Voss A. Nosocomial fungal infections: Candidemia. Diagn Microbiol Infect Dis 1999;34:213-20. (Pubitemid 29287215)
230. Hedderwick SA, Lyons MJ, Liu M, Vazquez JA, Kauffman CA. Epidemiology of yeast colonization in the intensive care unit. Eur J Clin Microbiol Infect Dis 2000;19:663-70.
231. Barchiesi F, Hollis RJ, Del PM, et al. Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis. Clin Infect Dis 1995;21:561-4.
232. Berger C, Frei R, Gratwohl A, Scheidegger C. Bottled lemon juice - a cryptic source of invasive Candida infections in the immunocompromised host. J Infect Dis 1988;158:654-5.
233. Charles PE, Dalle F, Aube H, et al. Candida spp. colonization significance in critically ill medical patients: A prospective study. Intensive Care Med 2005;31:393-400.
234. Garcia-San ML, Cobo J, Martos I, et al. Risk factors for candidemia in pediatric patients with congenital heart disease. Infect Control Hosp Epidemiol 2006;27:576-80. (Pubitemid 44023392)
235. Nucci M, Colombo AL. Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis 2002;21:209-11. (Pubitemid 34328006)
236. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989;149:2349-53.
237. Wenzel RP. Nosocomial candidemia: Risk factors and attributable mortality. Clin Infect Dis 1995;20:1531-4.
238. Kollef MH. Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? Clin Infect Dis 2006;(43 Suppl 2):S82-S88.
239. Piarroux R, Grenouillet F, Balvay P, et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004;32:2443-9. (Pubitemid 39648226)
240. Leon C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006;34:730-7.
241. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: Approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005;43:235-43. (Pubitemid 40867497)
242. Dupont H, Bourichon A, Paugam-Burtz C, Mantz J, Desmonts JM. Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 2003;31:752-7.
243. Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007;26:271-6. (Pubitemid 46572022)
244. Rho J, Shin JH, Song JW, et al. Molecular investigation of two consecutive nosocomial clusters of Candida tropicalis candiduria using pulsed-field gel electrophoresis. J Microbiol 2004;42:80-6. (Pubitemid 38952348)
245. Jang SJ, Han HL, Lee SH, et al. PFGE-based epidemiological study of an outbreak of Candida tropicalis candiduria: The importance of medical waste as a reservoir of nosocomial infection. Jpn J Infect Dis 2005;58:263-7.
246. Pittet D, Allegranzi B, Boyce J. The World Health Organization guidelines on hand hygiene in health care and their consensus recommendations. Infect Control Hosp Epidemiol 2009;30:611-22.
247. McGinley KJ, Larson EL, Leyden JJ. Composition and density of microflora in the subungual space of the hand. J Clin Microbiol 1988;26:950-3.
248. Hedderwick SA, McNeil SA, Lyons MJ, Kauffman CA. Pathogenic organisms associated with artificial fingernails worn by healthcare workers. Infect Control Hosp Epidemiol 2000;21:505-9. (Pubitemid 30647153)
249. McNeil SA, Foster CL, Hedderwick SA, Kauffman CA. Effect of hand cleansing with antimicrobial soap or alcohol-based gel on microbial colonization of artificial fingernails worn by health care workers. Clin Infect Dis 2001;32:367-72. (Pubitemid 32173621)
250. Ostrosky-Zeichner L. Prophylaxis or preemptive therapy of invasive candidiasis in the intensive care unit? Crit Care Med 2004;32:2552-3.
251. Vos MC, Endtz HP, Horst-Kreft D, et al. Candida krusei transmission among hematology patients resolved by adapted antifungal prophylaxis and infection control measures. J Clin Microbiol 2006;44:1111-4.
252. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev 2004;17:255-67. (Pubitemid 38534029)
253. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med 2003;348:1123-33. (Pubitemid 36337324)
254. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002;51:1-29.
255. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Infect Control Hosp Epidemiol 2001;22:222-42. (Pubitemid 32448672)
256. Wolf HH, Leithauser M, Maschmeyer G, et al. Central venous catheter-related infections in hematology and oncology: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2008;87:863-76.
257. Yamamura DL, Rotstein C, Nicolle LE, Ioannou S. Candidemia at selected Canadian sites: Results from the Fungal Disease Registry, 1992-1994. Fungal Disease Registry of the Canadian Infectious Disease Society. CMAJ 1999;160:493-9.
258. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11. (Pubitemid 12090793)
259. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668-72.
260. Baden LR. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 2005;353:1052-4. (Pubitemid 41262340)
261. Blijlevens NM, Donnelly JP, de Pauw BE. Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. Br J Haematol 2002;117:259-64. (Pubitemid 34451140)
262. Donnelly JP, Blijlevens NM, Verhagen CA. Can anything be done about oral mucositis? Ann Oncol 2003;14:505-7.
263. Trifilio S, Verma A, Mehta J. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: Heterogeneity of current clinical practice. Bone Marrow Transpl 2004;33:735-9. (Pubitemid 38499928)
264. Imataki O, Kami M, Kim SW, et al. A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation in Japan. Bone Marrow Transpl 2004;33:1173-9. (Pubitemid 38961473)
265. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol 2007;78:275-82. (Pubitemid 46365078)
266. Maertens JA, Frere P, Lass-Florl C, Heinz W, Cornely OA. Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer Suppl 2007;5:43-8. (Pubitemid 47193191)
267. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: A meta analysis of randomized-controlled clinical trials. Cancer 2002;94:3230-46. (Pubitemid 34670507)
268. Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003;21:4615-26. (Pubitemid 46594036)
269. Wingard JR, Carter CL, Walsh TJ, et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. Blood 2007;110:55a. (Abst)
270. Vehreschild JJ, Bohme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007;55:445-9. (Pubitemid 47628350)
271. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59. (Pubitemid 46148777)
272. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-47.
273. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-16.
274. Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006;50:143-7. (Pubitemid 43042914)
275. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:1527-33. (Pubitemid 38168674)
276. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999;28:331-40.
277. Yoshida M, Ohno R. Antimicrobial prophylaxis in febrile neutropenia. Clin Infect Dis 2004;(39 Suppl 1):S65-S67. (Pubitemid 38971480)
278. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for longterm antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138:705-13.
279. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055-61.
280. Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against infection in neutropenic patients - a meta-analysis of 16 randomized, controlled trials. Cancer 2000;89:1611-25.
281. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003;101:3365-72. (Pubitemid 36857916)
282. Glasmacher A, Prentice AG. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J Antimicrob Chemother 2005;(56 Suppl 1):i23-i32. (Pubitemid 41236087)
283. Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: A meta-analysis of randomised-controlled trials. Br J Haematol 2005;131:22-8. (Pubitemid 43899704)
284. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: Systematic review and meta-analysis. J Clin Oncol 2007;25:5471-89. (Pubitemid 350232225)
285. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-52.
286. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
287. Rubin RH. Overview: Pathogenesis of fungal infections in the organ transplant recipient. Transpl.Infect Dis 2002;(4 Suppl 3):12-7. (Pubitemid 34832431)
288. American Society of Transplantation. Fungal infections. Am J Transplant 2004;(4 Suppl 10):110-34.
289. Silveira FP, Husain S. Fungal infections in solid organ transplantation. Med Mycol 2007;45:305-20. (Pubitemid 46839801)
290. Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: A systematic review and meta-analysis. Liver Transpl 2006;12:850-8.
291. Playford EG, Webster AC, Sorrell TC, Craig JC. Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 2006;25:549-61. (Pubitemid 44379690)
292. Cornely OA, Ullmann AJ. Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death. Clin Infect Dis 2008;46:1626-7. (Pubitemid 351706747)
293. Fortun J, Martin-Davila P, Montejo M, et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation 2009;87:424-35.
294. Garbino J, Lorenzi P, Morel P, Romand JA. Kidney and pancreas transplantation: Postoperative infectious complications. Clin Microbiol Infect 1999;5:48-51. (Pubitemid 29055909)
295. Benedetti E, Gruessner AC, Troppmann C, et al. Intra-abdominal fungal infections after pancreatic transplantation: Incidence, treatment, and outcome. J Am Coll Surg 1996;183:307-16. (Pubitemid 26332741)
296. Singh N. Antifungal prophylaxis in solid-organ transplant recipients: Considerations for clinical trial design. Clin Infect Dis 2004;(39 Suppl 4):S200-S206. (Pubitemid 40169347)
297. Woeste G, Wullstein C, Vogt J, Zapletal C, Bechstein WO. Value of donor swabs for intra-abdominal infection in simultaneous pancreas-kidney transplantation. Transplantation 2003;76:1073-8. (Pubitemid 37280836)
298. Steurer W, Bonatti H, Obrist P, et al. Incidence of intraabdominal infection in a consecutive series of 40 enteric-drained pancreas transplants with FK506 and MMF immunosuppression. Transpl Int 2000;(13 Suppl 1):S195-S198.
299. Humar A, Kandaswamy R, Granger D, Gruessner RW, Gruessner AC, Sutherland DE. Decreased surgical risks of pancreas transplantation in the modern era. Ann Surg 2000;231:269-75. (Pubitemid 30078811)
300. Stratta RJ. Ganciclovir/acyclovir and fluconazole prophylaxis after simultaneous kidney-pancreas transplantation. Transplant Proc 1998;30:262. (Pubitemid 28207147)
301. Smets YF, van der Pijl JW, van Dissel JT, Ringers J, de Fijter JW, Lemkes HH. Infectious disease complications of simultaneous pancreas kidney transplantation. Nephrol Dial Transplant 1997;12:764-71. (Pubitemid 27170435)
302. Berger N, Guggenbichler S, Steurer W, et al. Bloodstream infection following 217 consecutive systemic-enteric drained pancreas transplants. BMC Infect Dis 2006;6:127.
303. Strahilevitz J, Sugar AM, Engelhard D. Fluconazole in transplant recipients: Options and limitations. Transpl Infect Dis 2000;2:62-71. (Pubitemid 30262724)
304. Abbott KC, Hypolite I, Poropatich RK, et al. Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis 2001;3:203-11. (Pubitemid 34051921)
305. Martinez-Marcos F, Cisneros J, Gentil M, et al. Prospective study of renal transplant infections in 50 consecutive patients. Eur J Clin Microbiol Infect Dis 1994;13:1023-8.
306. Nampoory MR, Khan ZU, Johny KV, et al. Invasive fungal infections in renal transplant recipients. J Infect 1996;33:95-101. (Pubitemid 26336421)
307. Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation: Current epidemiology and associated risk factors. Clin Transplant 2006;20:401-9. (Pubitemid 43983815)
308. Grossi P, Farina C, Fiocchi R, Dalla GD. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: A multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000;70:112-6. (Pubitemid 30490761)
309. Kubak BM. Fungal infection in lung transplantation. Transpl Infect Dis 2002;(4 Suppl 3):24-31. (Pubitemid 34832433)
310. Dummer JS, Lazariashvilli N, Barnes J, Ninan M, Milstone AP. A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant 2004;23:1376-81. (Pubitemid 40018160)
311. Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine (Baltimore) 1996;75:142-56.
312. Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001;32:1191-200. (Pubitemid 32427691)
313. Lipsett PA. Surgical critical care: Fungal infections in surgical patients. Crit Care Med 2006;34:S215-S224. (Pubitemid 44253708)
314. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001;33:177-86. (Pubitemid 32643332)
315. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990.
316. National Nosocomial Infections Surveillance System. J Infect Dis 1993;167:1247-51.
317. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-5.
318. Charles PE, Doise JM, Quenot JP, et al. Candidemia in critically ill patients: Difference of outcome between medical and surgical patients. Intensive Care Med 2003;29:2162-9. (Pubitemid 38030666)
319. Garey KW, Neuhauser MM, Bearden DT, et al. Evaluation of antifungals in the surgical intensive care unit: A multi-institutional study. Mycoses 2006;49:226-31.
320. Savino JA, Agarwal N, Wry P, Policastro A, Cerabona T, Austria L. Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. J Trauma 1994;36:20-5.
321. Ables A, Blumer N, Valainis G, Godenick M, Kajdasz D, Palesch Y. Fluconazole prophylaxis of severe Candida infection in trauma and postsurgical patients: A prospective, double-blind, randomized, placebo-controlled trial. Infect Dis Clin Pract 2000;9:169-75. (Pubitemid 30241173)
322. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: Systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006;57:628-38.
323. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev 2006;CD004920.
324. Villatoro E, Bassi C, Larvin M. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev 2006;CD002941.
325. UK Working Party on Acute Pancreatitis. UK guidelines for the management of acute pancreatitis. Gut 2005;(54 Suppl 3):iii1-iii9.
326. Uhl W, Warshaw A, Imrie C, et al. IAP Guidelines for the surgical management of acute pancreatitis. Pancreatology 2002;2:565-73. (Pubitemid 35365347)
327. Nathens AB, Curtis JR, Beale RJ, et al. Management of the critically ill patient with severe acute pancreatitis. Crit Care Med 2004;32:2524-36. (Pubitemid 39648238)
328. Isenmann R, Schwarz M, Rau B, Trautmann M, Schober W, Beger HG. Characteristics of infection with Candida species in patients with necrotizing pancreatitis. World J Surg 2002;26:372-6. (Pubitemid 36920418)
329. Gloor B, Muller CA, Worni M, et al. Pancreatic infection in severe pancreatitis: The role of fungus and multiresistant organisms. Arch Surg 2001;136:592-6. (Pubitemid 32417551)
330. Isaji S, Takada T, Kawarada Y, et al. JPN Guidelines for the management of acute pancreatitis: Surgical management. J Hepatobiliary Pancreat Surg 2006;13:48-55. (Pubitemid 43193674)
331. Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: Current epidemiological trends. Clin Infect Dis 2006;43:S3-S14. (Pubitemid 44078892)
332. Hoerauf A, Hammer S, Muller-Myhsok B, Rupprecht H. Intra-abdominal Candida infection during acute necrotizing pancreatitis has a high prevalence and is associated with increased mortality. Crit Care Med 1998;26:2010-5. (Pubitemid 29016683)
333. Gotzinger P, Wamser P, Barlan M, Sautner T, Jakesz R, Fugger R. Candida infection of local necrosis in severe acute pancreatitis is associated with increased mortality. Shock 2000;14:320-3.
334. Grewe M, Tsiotos GG, Luque de-Leon E, Sarr MG. Fungal infection in acute necrotizing pancreatitis. J Am Coll Surg 1999;188:408-14. (Pubitemid 29162699)
335. Connor S, Alexakis N, Neal T, et al. Fungal infection but not type of bacterial infection is associated with a high mortality in primary and secondary infected pancreatic necrosis. Dig Surg 2004;21:297-304. (Pubitemid 39370395)
336. Aloia T, Solomkin J, Fink AS, et al. Candida in pancreatic infection: A clinical experience. Am Surg 1994;60:793-6. (Pubitemid 24299092)
337. De Waele JJ, Vogelaers D, Blot S, Colardyn F. Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. Clin Infect Dis 2003;37:208-13. (Pubitemid 36930351)
338. He YM, Lv XS, Ai ZL, et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World J Gastroenterol 2003;9:2619-21.
339. Chamilos G, Luna MA, Lewis RE. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center; an autopsy study over a 15-year period (1980-2003). Haematologica 2006;91:986-9.
340. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study. Clin Infect Dis 2005;41:1242-50. (Pubitemid 41534660)
341. Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: A randomized, controlled trial. Clin Infect Dis 2009;48:1042-51.
342. Marchetti O, Cordonnier C, Calandra T. Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. Eur J Cancer Suppl 2007;5:32-42. (Pubitemid 47187743)
343. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000;31:1155-63. (Pubitemid 32295443)
344. Goldberg E, Gafter-Gvili A, Robenshtok E, Leibovici L, Paul M. Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis. Eur J Cancer 2008;44:2192-203.
345. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51. (Pubitemid 34194843)
346. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-71. (Pubitemid 29114295)
347. Viscoli C, Castagnola E, Van Lint MT, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: A pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 1996;32A:814-20.
348. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000;108:282-9. (Pubitemid 30110456)
349. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001;135:412-22. (Pubitemid 32845866)
350. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402.
351. Jorgensen KJ, Johansen HK, Gotzsche PC. Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations. Trials 2006;7:3.
352. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34. (Pubitemid 34438861)
353. Bow EJ. Considerations in the approach to invasive fungal infection in patients with haematological malignancies. Br J Haematol 2008;140:133-52. (Pubitemid 350284490)
354. Betts R, Glasmacher A, Maertens J, et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 2006;106:466-73. (Pubitemid 43100459)
355. Anaissie EJ, Vartivarian SE, bi-Said D, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study. Am J Med 1996;101:170-6. (Pubitemid 26296778)
356. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:2472-82. (Pubitemid 46919773)
357. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-93. (Pubitemid 47580382)
358. Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995;21:994-6.
359. Thaler M, Pastakia B, Shawker TH, O'Leary T, Pizzo PA. Hepatic candidiasis in cancer patients: The evolving picture of the syndrome. Ann Intern Med 1988;108:88-100. (Pubitemid 18081176)
360. Flynn PM, Shenep JL, Crawford R, Hughes WT. Use of abdominal computed tomography for identifying disseminated fungal infection in pediatric cancer patients. Clin Infect Dis 1995;20:964-70.
361. Talbot GH, Provencher M, Cassileth PA. Persistent fever after recovery from granulocytopenia in acute leukemia. Arch Intern Med 1988;148:129-35. (Pubitemid 18071388)
362. Kauffman CA, Bradley SF, Ross SC, Weber DR. Hepatosplenic candidiasis: Successful treatment with fluconazole. Am J Med 1991;91:137-41.
363. Anaissie E, Bodey GP, Kantarjian H, et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991;91:142-50.
364. Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997;41:1944-8. (Pubitemid 27383233)
365. Legrand F, Lecuit M, Dupont B, et al. Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clin Infect Dis 2008;46:696-702. (Pubitemid 351321553)
366. Sendid B, Poirot JL, Tabouret M, et al. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 2002;51:433-42. (Pubitemid 34450601)
367. Philip A, Odabasi Z, Matiuzzi G, et al. Syscan3, a kit for detection of anti-Candida antibodies for diagnosis of invasive candidiasis. J Clin Microbiol 2005;43:4834-5. (Pubitemid 41298288)
368. Takesue Y, Kakehashi M, Ohge H, et al. Combined assessment of beta-D-glucan and degree of Candida colonization before starting empiric therapy for candidiasis in surgical patients. World J Surg 2004;28:625-30. (Pubitemid 38802803)
369. McMullan R, Metwally L, Coyle PV, et al. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis 2008;46:890-6. (Pubitemid 351417192)
370. Edwards JE Jr, Bodey GP, Bowden RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997;25:43-59.
371. Shan YS, Sy ED, Wang ST, Lee JC, Lin PW. Early presumptive therapy with fluconazole for occult Candida infection after gastrointestinal surgery. World J Surg 2006;30:119-26. (Pubitemid 43081623)
372. Chen H, Suda KJ, Turpin RS, Pai MP, Bearden DT, Garey KW. High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: A cost-effectiveness analysis. Curr Med Res Opin 2007;23:1057-65. (Pubitemid 46799589)
373. Azoulay E, Timsit JF, Tafflet M, et al. Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest 2006;129:110-7. (Pubitemid 43265250)
374. Schuster MG, Edwards JE Jr, Sobel JD, et al. Empirical fluconazole versus placebo for intensive care unit patients: A randomized trial. Ann Intern Med 2008;149:83-90. (Pubitemid 352008596)
375. St-Germain G, Laverdiere M, Pelletier R, et al. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005. Can J Infect Dis Med Microbiol 2008;19:55-62.
376. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis 2006;43:25-31. (Pubitemid 43939072)
377. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640-5. (Pubitemid 41233011)
378. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96. (Pubitemid 43810035)
379. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-55. (Pubitemid 30485502)
380. Gafter-Gvili A, Vidal L, Goldberg E, Leibovici L, Paul M. Treatment of invasive candidal infections: Systematic review and meta-analysis. Mayo Clin Proc 2008;83:1011-21.
381. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003;37:634-43. (Pubitemid 37100802)
382. Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001;39:3254-9. (Pubitemid 32830323)
383. Cuenca-Estrella M, Rodriguez D, Almirante B, et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: Results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005;55:194-9.
384. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol 2006;44:1782-7.
385. Macphail GL, Taylor GD, Buchanan-Chell M, Ross C, Wilson S, Kureishi A. Epidemiology, treatment and outcome of candidemia: A five-year review at three Canadian hospitals. Mycoses 2002;45:141-5. (Pubitemid 34743916)
386. St-Germain G, Laverdiere M, Pelletier R, et al. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: Results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 2001;39:949-53. (Pubitemid 32209705)
387. Rabinovici R, Szewczyk D, Ovadia P, Greenspan JR, Sivalingam JJ. Candida pericarditis: Clinical profile and treatment. Ann Thorac Surg 1997;63:1200-4. (Pubitemid 27191705)
388. Nicolle LE, Rotstein C, Bourgault AM, St-Germain G, Garber G. Invasive fungal infections in Canada 1992-1994. Can J Infect Dis 1998;9:347-52.
389. Bille J, Edson RS, Roberts GD. Clinical evaluation of the lysis-centrifugation blood culture system for the detection of fungemia and comparison with a conventional biphasic broth blood culture system. J Clin Microbiol 1984;19:126-8. (Pubitemid 14183561)
390. Franklin WG, Simon AB, Sodeman TM. Candida myocarditis without valvulitis. Am J Cardiol 1976;38:924-8.
391. Lipton SA, Hickey VF, Morris JH. Candidal infection in the central nervous system. Am J Med 1984;76:101-8. (Pubitemid 14216367)
392. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis. Clin Infect Dis 2005;41:1232-9. (Pubitemid 41532664)
393. Becker WK, Cioffi WG Jr, McManus AT, et al. Fungal burn wound infection. A 10-year experience. Arch Surg 1991;126:44-8.
394. Launay O, Lortholary O, Bouges-Michel C, Jarrousse B, Bentata M, Guillevin L. Candidemia: A nosocomial complication in adults with late-stage AIDS. Clin Infect Dis 1998;26:1134-41. (Pubitemid 28215478)
395. Tumbarello M, Tacconelli E, de Gaetano DK, Morace G, Fadda G, Cauda R. Candidemia in HIV-infected subjects. Eur J Clin Microbiol Infect Dis 1999;18:478-83. (Pubitemid 29531187)
396. Pittet D, Wenzel RP. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med 1995;155:1177-84.
397. Sobel JD. The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia. Curr Infect Dis Rep 2006;8:427-33. (Pubitemid 44717978)
398. Lupetti A, Tavanti A, Davini P, et al. Horizontal transmission of Candida parapsilosis candidemia in a neonatal intensive care unit. J Clin Microbiol 2002;40:2363-9. (Pubitemid 34747334)
399. Opilla M. Epidemiology of bloodstream infection associated with parenteral nutrition. Am J Infect Control 2008;36:S173-S178.
400. Pyrgos V, Ratanavanich K, Donegan N, Veis J, Walsh TJ, Shoham S. Candida bloodstream infections in hemodialysis recipients. Med Mycol 2008:1-5.
401. Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000;30:14-8. (Pubitemid 30067055)
402. Jacobs LG, Skidmore EA, Cardoso LA, Ziv F. Bladder irrigation with amphotericin B for treatment of fungal urinary tract infections. Clin Infect Dis 1994;18:313-8. (Pubitemid 24086297)
403. Sanchez-Portocarrero J, Perez-Cecilia E, Corral O, Romero-Vivas J, Picazo JJ. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis 2000;37:169-79. (Pubitemid 30440728)
404. Scarcella A, Pasquariello MB, Giugliano B, Vendemmia M, De LA. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 1998;17:146-8.
405. Prabhu RM, Orenstein R. Failure of caspofungin to treat brain abscesses secondary to Candida albicans prosthetic valve endocarditis. Clin Infect Dis 2004;39:1253-4. (Pubitemid 40169330)
406. Edwards JE Jr, Foos RY, Montgomerie JZ, Guze LB. Ocular manifestations of Candida septicemia: Review of seventy-six cases of hematogenous Candida endophthalmitis. Medicine (Baltimore) 1974;53:47-75.
407. Akler ME, Vellend H, McNeely DM, Walmsley SL, Gold WL. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis 1995;20:657-64.
408. Sim JP, Kho BC, Liu HS, Yung R, Chan JC. Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: Successful treatment with caspofungin. Hong Kong Med J 2005;11:120-3. (Pubitemid 40545516)
409. Tunkel AR, Thomas CY, Wispelwey B. Candida prosthetic arthritis: Report of a case treated with fluconazole and review of the literature. Am J Med 1993;94:100-3. (Pubitemid 23021178)
410. Miller DJ, Mejicano GC. Vertebral osteomyelitis due to Candida species: Case report and literature review. Clin Infect Dis 2001;33:523-30. (Pubitemid 32709586)
411. Steinbach WJ, Perfect JR, Cabell CH, et al. A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infect 2005;51:230-47. (Pubitemid 41554832)
412. Benoit D, Decruyenaere J, Vandewoude K, et al. Management of candidal thrombophlebitis of the central veins: Case report and review. Clin Infect Dis 1998;26:393-7. (Pubitemid 28083953)
413. Leon C, Ruiz-Santana S, Saavedra P, et al. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: A prospective multicenter study. Crit Care Med 2009;37:1624-33.